SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

$ELAN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ELAN alert in real time by email
SC 13G/A 1 d465178dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 2)*

 

 

Elanco Animal Health Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

28414H103

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP NO. 28414H103    13G    PAGE 2 OF 4 PAGES

 

  1   

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Dodge & Cox    94-1441976

  2   

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ☐        (b)  ☐

 

N/A

  3   

  SEC USE ONLY

 

  4   

CITIZENSHIP OR PLACE OF ORGANIZATION

 

California – U.S.A.

NUMBER OF

SHARES

 BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

      5     

SOLE VOTING POWER

 

80,123,275

      6     

SHARED VOTING POWER

 

0

      7     

SOLE DISPOSITIVE POWER

 

84,775,075

      8   

SHARED DISPOSITIVE POWER

 

0

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

84,775,075

10   

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

N/A

11   

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

17.9%

12   

TYPE OF REPORTING PERSON*

 

IA


Item 1(a)

Name of Issuer:

Elanco Animal Health Incorporated

 

Item 1(b)

Address of Issuer’s Principal Executive Offices:

2500 Innovation Way

Greenfield, Indiana 46140

 

Item 2(a)

Name of Person Filing:

Dodge & Cox

 

Item 2(b)

Address of the Principal Office or, if none, Residence:

555 California Street, 40th Floor

San Francisco, CA 94104

 

Item 2(c)

Citizenship:

California - U.S.A.

 

Item 2(d)

Title of Class of Securities:

Common Stock

 

Item 2(e)

CUSIP Number:

28414H103

 

Item 3

If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

(e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

 

Item 4

Ownership:

 

  (a)

Amount Beneficially Owned:

84,775,075

 

  (b)

Percent of Class:

17.9%


  (c)

Number of shares as to which such person has:

 

  (i)

sole power to vote or direct the vote:

80,123,275

 

  (ii)

shared power to vote or direct the vote:

0

 

  (iii)

sole power to dispose or to direct the disposition of:

84,775,075

 

  (iv)

shared power to dispose or to direct the disposition of:

0

 

Item 5

Ownership of Five Percent or Less of a Class:

Not applicable.

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person:

The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Elanco Animal Health Incorporated.

Dodge & Cox Stock Fund, an investment company registered under the Investment Company Act of 1940, has an interest of 54,903,300 or 11.6%, of the class of securities reported herein.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable.

 

Item 8

Identification and Classification of Members of the Group:

Not applicable.

 

Item 9

Notice of Dissolution of a Group:

Not applicable.

 

Item 10

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

 

DODGE & COX
By:   /S/ Katherine M. Primas
Name:   Katherine M. Primas
Title:   Chief Compliance Officer
Get the next $ELAN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELAN

DatePrice TargetRatingAnalyst
12/9/2024$18.00Buy
UBS
12/2/2024$14.00Market Perform
Leerink Partners
9/19/2024$17.00 → $15.00Overweight → Equal-Weight
Morgan Stanley
1/5/2024$13.00 → $20.00Hold → Buy
Stifel
12/19/2023$17.00Buy
Jefferies
12/15/2023$16.00Equal-Weight → Overweight
Morgan Stanley
12/7/2023$18.00Outperform
Exane BNP Paribas
4/20/2023$14.00Equal Weight → Overweight
Barclays
More analyst ratings

$ELAN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

    GREENFIELD, Ind., Feb. 25, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the company's innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle. Medgene reports the vaccine has met all requirements of the U.S. Department of Agriculture's (USDA) platform technology guidelines and is in the final stages of review for conditional license approval. While the poultry in

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco to Participate in Upcoming Investor Conferences

    GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that the Company will participate in the following investor conferences. On Thursday, February 27, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2025 Animal Health Summit at 12:30 p.m. ET. On Monday, March 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference at 3:10 p.m. ET. On Tuesday, March 11, Todd Young, executive vice president and CFO,

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Launches Pet Protect™ From the Makers of Advantage®: Veterinarian-Formulated Supplements for Complete Pet Wellness

    Pet Protect offers a comprehensive line of veterinarian-formulated, science-backed supplements.The U.S. pet supplement market is growing as pet parents increasingly desire proactive wellness options.Pet Protect features products for both dogs and cats, including joint health, multivitamins, Omega-3, fast-acting calming, allergy and immune support, digestive function support and more.The launch of Pet Protect from the Makers of Advantage strengthens Elanco's position as a leader in the pet health market and offers a science-backed brand to the supplements category. The Advantage brand is a trusted leader in pet health for 25 years.GREENFIELD, Ind., Feb. 20, 2025 /PRNewswire/ -- Elanco Animal

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELAN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ELAN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELAN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELAN
SEC Filings

See more

$ELAN
Leadership Updates

Live Leadership Updates

See more
  • Elanco Strengthens Board of Directors with Addition of Stacey Ma

    Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

    New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

    GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELAN
Financials

Live finance-specific insights

See more
  • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

    GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Acquires Speke Contract Manufacturing Facility, Securing Key Supply Chain

    GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement

    GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELAN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more